• vcard
D 314.552.6876
F 314.754.8390
  • Education
    • LL.M., Washington University in St. Louis
    • J.D., Washington University in St. Louis
    • B.A., Knox College
Andrew Hoyne practices business and corporate law focused upon the representation of life sciences and other technology-based companies. His clients include/have included multi-billion dollar corporations, Big Ten universities, emerging companies and investors. Andy's life science practice includes pharmaceuticals, medical devices, research services, chemical and biochemical products, agriculture, and bio-energy clients. He has also represented clients in the fields of energy; information technology; food products, ingredients and flavors; electric motors; imaging devices; powders for industrial applications; spectroscopic analytical technology; and other technical and industrial applications.

Andy also represents venture capital funds as well as corporate and other investors with respect to fund investment, structure and management in the areas of life sciences, information technology, financial technology, cyber security, agriculture and energy.

Prior to entering private practice, Andy was associate general counsel for Invitron, a publicly-held bio-pharmaceutical contract manufacturing and product development company, and assistant general counsel for The Seven-Up Company, a soft drink and food products company. From 2011-2015, Andy was the practice leader for the Startup Ventures practice segment in Polsinelli’s St. Louis office. He also served as one of the co-leaders of the firm’s national Startup Ventures practice segment.
Mr. Hoyne has represented clients in transactions totaling hundreds of millions of dollars.

He has represented clients in a wide range of life sciences projects representing emerging companies, established companies and research institutions. This experience includes representing clients in partnering agreements with Monsanto, Zimmer, Sangamo, Phillips, Bristol-Myers Squibb, Introgen, Viasys, and other companies and client exits to Monsanto and Avant Pharmaceuticals.  Matters include the following:
  • An ag-bio company, from start-up, through multiple rounds of venture financing and a $71 million sale to a major public corporation
  • An ag-bio company in a collaborative research and license agreement with a major public corporation relating to nematode resistant crops
  • A major public corporation in a strategic alliance with a public life sciences company valued at approximately $35 million focused upon zinc finger proteins
  • A major public corporation in multiple contracts and licensing agreements including in the field of RNAi
  • An emerging targeted molecular imaging company, in a partnering transaction with a major public corporation in the development and commercialization of novel molecular imaging agents
  • An emerging targeted molecular imaging company in a product development agreement with a major public corporation
  • An emerging orthobiologics company, in a strategic partnership with a major public corporation with respect to the development and commercialization of allograft tissue
  • An emerging anti-cancer company in a collaboration and license agreement with a public corporation
  • An emerging brain-wave company in a partnering agreement with a public corporation
  • An emerging human and animal vaccines company in its sale to a public corporation
  • The medical device arm of a major public corporation in the $85 million acquisition of a medical device business from a major public corporation
  • Multiple life science clients in over $100 million of venture capital funding from venture capital funds, angels, angel networks, corporations, state agencies, and regional accelerators
  • Multiple emerging and major corporate clients in multiple life sciences license, master service, confidentiality, manufacturing, research, collaboration, distribution, clinical study, and other agreements
Publications & Presentations
Plan for Funding
Missouri Venture Forum 
Panel Moderator
June 13, 2016
Publications & Presentations
Corporate Partnering
Center for Emerging Technologies
Program coordinator and moderator
December 11, 2013
Publications & Presentations
Current Funding for Emerging Technology Companies
Missouri Venture Forum
November 21, 2013
Publications & Presentations
St. Louis Business Journal Program
October 30, 2013
Publications & Presentations
Corporate Partnering
Licensing Executives Society, St. Louis Chapter
September 20, 2013
Publications & Presentations
Center for Emerging Technologies
August 29, 2013
Publications & Presentations
St. Louis Arch Angels
August 28, 2013
Publications & Presentations
Starting a Technology Company
Washington University School of Engineering Faculty
August 26, 2013
Publications & Presentations
Advanced Technology Transfer
Center for Emerging Technologies
Program Coordinator and Moderator; St. Louis
May 15, 2013
Publications & Presentations
Avoiding Common Mistakes When Starting Your First Company; Raising Capital and Negotiating Terms
The Medical Entrepreneur Symposium 2013
Presentation given in Delray Beach, Florida
April 20, 2013
Related News

Past Events